These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

806 related articles for article (PubMed ID: 7564517)

  • 41. Quantification of fusion transcript reveals a subgroup with distinct biological properties and predicts relapse in BCR/ABL-positive ALL: implications for residual disease monitoring.
    Zaliova M; Fronkova E; Krejcikova K; Muzikova K; Mejstrikova E; Stary J; Trka J; Zuna J
    Leukemia; 2009 May; 23(5):944-51. PubMed ID: 19158828
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The PML-RAR alpha transcript in long-term follow-up of acute promyelocytic leukemia patients.
    Gameiro P; Vieira S; Carrara P; Silva AL; Diamond J; Botelho de Sousa A; Mehta AB; Prentice HG; Guimarães JE; Hoffbrand AV; Foroni L; Parreira A
    Haematologica; 2001 Jun; 86(6):577-85. PubMed ID: 11418366
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Minimal residual disease detection in childhood precursor-B-cell acute lymphoblastic leukemia: relation to other risk factors. A Children's Oncology Group study.
    Borowitz MJ; Pullen DJ; Shuster JJ; Viswanatha D; Montgomery K; Willman CL; Camitta B;
    Leukemia; 2003 Aug; 17(8):1566-72. PubMed ID: 12886244
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow.
    Basso G; Veltroni M; Valsecchi MG; Dworzak MN; Ratei R; Silvestri D; Benetello A; Buldini B; Maglia O; Masera G; Conter V; Arico M; Biondi A; Gaipa G
    J Clin Oncol; 2009 Nov; 27(31):5168-74. PubMed ID: 19805690
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term follow-up of residual disease in acute lymphoblastic leukemia patients in complete remission using clonogeneic IgH probes and the polymerase chain reaction.
    Nizet Y; Van Daele S; Lewalle P; Vaerman JL; Philippe M; Vermylen C; Cornu G; Ferrant A; Michaux JL; Martiat P
    Blood; 1993 Sep; 82(5):1618-25. PubMed ID: 8364210
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.
    Topp MS; Kufer P; Gökbuget N; Goebeler M; Klinger M; Neumann S; Horst HA; Raff T; Viardot A; Schmid M; Stelljes M; Schaich M; Degenhard E; Köhne-Volland R; Brüggemann M; Ottmann O; Pfeifer H; Burmeister T; Nagorsen D; Schmidt M; Lutterbuese R; Reinhardt C; Baeuerle PA; Kneba M; Einsele H; Riethmüller G; Hoelzer D; Zugmaier G; Bargou RC
    J Clin Oncol; 2011 Jun; 29(18):2493-8. PubMed ID: 21576633
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group.
    Eckert C; Henze G; Seeger K; Hagedorn N; Mann G; Panzer-Grümayer R; Peters C; Klingebiel T; Borkhardt A; Schrappe M; Schrauder A; Escherich G; Sramkova L; Niggli F; Hitzler J; von Stackelberg A
    J Clin Oncol; 2013 Jul; 31(21):2736-42. PubMed ID: 23775972
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of pretransplant minimal residual disease after cord blood transplantation for childhood acute lymphoblastic leukemia in remission: an Eurocord, PDWP-EBMT analysis.
    Ruggeri A; Michel G; Dalle JH; Caniglia M; Locatelli F; Campos A; de Heredia CD; Mohty M; Hurtado JM; Bierings M; Bittencourt H; Mauad M; Purtill D; Cunha R; Kabbara N; Gluckman E; Labopin M; Peters C; Rocha V
    Leukemia; 2012 Dec; 26(12):2455-61. PubMed ID: 22555150
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia.
    Flohr T; Schrauder A; Cazzaniga G; Panzer-Grümayer R; van der Velden V; Fischer S; Stanulla M; Basso G; Niggli FK; Schäfer BW; Sutton R; Koehler R; Zimmermann M; Valsecchi MG; Gadner H; Masera G; Schrappe M; van Dongen JJ; Biondi A; Bartram CR;
    Leukemia; 2008 Apr; 22(4):771-82. PubMed ID: 18239620
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Flow cytometry and IG/TCR quantitative PCR for minimal residual disease quantitation in acute lymphoblastic leukemia: a French multicenter prospective study on behalf of the FRALLE, EORTC and GRAALL.
    Garand R; Beldjord K; Cavé H; Fossat C; Arnoux I; Asnafi V; Bertrand Y; Boulland ML; Brouzes C; Clappier E; Delabesse E; Fest T; Garnache-Ottou F; Huguet F; Jacob MC; Kuhlein E; Marty-Grès S; Plesa A; Robillard N; Roussel M; Tkaczuk J; Dombret H; Macintyre E; Ifrah N; Béné MC; Baruchel A
    Leukemia; 2013 Feb; 27(2):370-6. PubMed ID: 23070018
    [TBL] [Abstract][Full Text] [Related]  

  • 51. T cell receptor gamma gene rearrangements as targets for detection of minimal residual disease in acute lymphoblastic leukemia by real-time quantitative PCR analysis.
    van der Velden VH; Wijkhuijs JM; Jacobs DC; van Wering ER; van Dongen JJ
    Leukemia; 2002 Jul; 16(7):1372-80. PubMed ID: 12094263
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Persistence of self-renewing leukemia cell progenitors during remission in children with B-precursor acute lymphoblastic leukemia.
    Estrov Z; Ouspenskaia MV; Felix EA; McClain KL; Lee MS; Harris D; Pinkel DP; Zipf TF
    Leukemia; 1994 Jan; 8(1):46-52. PubMed ID: 8289497
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Detectable molecular residual disease at the beginning of maintenance therapy indicates poor outcome in children with T-cell acute lymphoblastic leukemia.
    Dibenedetto SP; Lo Nigro L; Mayer SP; Rovera G; Schilirò G
    Blood; 1997 Aug; 90(3):1226-32. PubMed ID: 9242556
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Monitoring of minimal residual disease in children with acute lymphoblastic leukemia and its prognostic significance].
    Xu XJ; Tang YM; Song H; Shi SW; Yang SL; Shen HQ; Wei J; Xu WQ; Pan BH; Zhao FY
    Zhonghua Er Ke Za Zhi; 2010 Mar; 48(3):180-4. PubMed ID: 20426951
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia.
    Neale GA; Coustan-Smith E; Stow P; Pan Q; Chen X; Pui CH; Campana D
    Leukemia; 2004 May; 18(5):934-8. PubMed ID: 15029212
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clonal evolution of immunoglobulin heavy chain rearrangements in childhood B-precursor acute lymphoblastic leukemia after engraftment in SCID mice.
    Steenbergen EJ; Verhagen OJ; Nibbering CP; van den Berg H; van Leeuwen EF; Behrendt H; von dem Borne AE; van der Schoot CE
    Leukemia; 1996 Sep; 10(9):1471-8. PubMed ID: 8751465
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Kinetics of minimal residual disease during induction/consolidation therapy in standard-risk adult B-lineage acute lymphoblastic leukemia.
    Scholten C; Födinger M; Mitterbauer M; Laczika K; Mitterbauer G; Haas OA; Knöbl P; Schwarzinger I; Thalhammer R; Purtscher B
    Ann Hematol; 1995 Oct; 71(4):155-60. PubMed ID: 7578520
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Sequential monitoring of minimal residual disease in acute lymphoblastic leukemia: 7-year experience in a pediatric hematology/oncology unit.
    Katsibardi K; Moschovi MA; Braoudaki M; Papadhimitriou SI; Papathanasiou C; Tzortzatou-Stathopoulou F
    Leuk Lymphoma; 2010 May; 51(5):846-52. PubMed ID: 20350276
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Clinical research on clearance of leukemic cell during induction of remission therapy in children with precursor B cell acute lymphoblastic leukemia].
    Yi ZG; Cui L; Gao C; Jin M; Zhang RD; Li ZG; Wu MY
    Zhonghua Er Ke Za Zhi; 2011 Mar; 49(3):170-4. PubMed ID: 21575363
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Residual disease detection using fluorescent polymerase chain reaction at 20 weeks of therapy predicts clinical outcome in childhood acute lymphoblastic leukemia.
    Evans PA; Short MA; Owen RG; Jack AS; Forsyth PD; Shiach CR; Kinsey S; Morgan GJ
    J Clin Oncol; 1998 Nov; 16(11):3616-27. PubMed ID: 9817283
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.